β³ Fetching live dividend data...
Home βΊ Calculator βΊ TRSBF Dividend Calculator 2026
3SBio Inc. Β· OTC
Price: $2.15 Β· Annual div: $0.03/share Β· Frequency: quarterly Β· Payout ratio: 50% Β· Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in TRSBF β $10.39M in 10 years Β· $12.55/month
3SBio Inc. is a China-based investment holding company deeply engaged in the biopharmaceutical sector, encompassing the entire value chain from research and development to manufacturing, marketing, and sales of its innovative products. The company's extensive biopharmaceutical portfolio caters to a wide array of therapeutic needs. This includes treatments for various blood disorders like TPIAO (for chemotherapy-induced or immune thrombocytopenia), EPIAO and SEPO (recombinant erythropoietins for anemia), and SPARIN (a low-molecular-weight heparin for deep vein thrombosis prophylaxis and treatment, as well as for preventing clotting during hemodialysis), alongside Aiyishu for iron-deficiency anemia. Its autoimmune and inflammatory disease offerings feature YISAIPU, a tumor necrosis factor inhibitor effective against rheumatoid arthritis, ankylosing spondylitis, and psoriasis. In the oncology domain, 3SBio provides Cipterbin for HER2-positive metastatic breast cancer (in combination with chemotherapy), Intefen (a recombinant human interferon for lymphatic/hematopoietic malignancies and viral infections), and Inleusin (human interleukin-2 for renal cell carcinoma, melanoma, and thoracic fluid accumulation). Other specialized products address conditions such as male alopecia and alopecia areata (Mandi), acute rejection post-renal transplant (Xenopax), glycemic control in type 2 diabetes (Byetta), and diabetic retinopathy (Qiming Keli). In addition to its pharmaceutical operations, 3SBio diversifies its activities through services encompassing trading, project management, consulting, technology, and agriculture. The company has forged strategic collaboration agreements with a multitude of international partners, including prominent names like AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and the Dana-Farber Cancer Institute. Established in 1993, the company maintains its headquarters in Shenyang, China.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. Β· Privacy Policy
Ready to invest? Open TRSBF position with:
Real after-tax yield depends on where you live and how you hold TRSBF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| πΊπΈ Roth IRA / 401k | 0% | 1.48% | -1.32% | $148 / yr |
| πΊπΈ US Taxable (15%) β | 15% | 1.26% | -1.54% | $126 / yr |
| πΊπΈ US Taxable (20%) | 20% | 1.18% | -1.62% | $118 / yr |
| π¬π§ UK ISA | 0% | 1.48% | -1.32% | $148 / yr |
| π¬π§ UK Taxable | 8.75% | 1.35% | -1.45% | $135 / yr |
| π¨π¦ TFSA | 0% | 1.48% | -1.32% | $148 / yr |
| π¨π¦ CA Taxable | 25% | 1.11% | -1.69% | $111 / yr |
| π¦πΊ Super (pension) | 15% | 1.26% | -1.54% | $126 / yr |
| π¦πΊ AU Taxable | 30% | 1.04% | -1.76% | $104 / yr |
| π©πͺ DE Taxable | 26.375% | 1.09% | -1.71% | $109 / yr |
| π«π· FR Taxable | 30% | 1.04% | -1.76% | $104 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $0.03/share/yr Β· πΊπΈ US Taxable (15%) Β· static projection (no growth assumed).
TRSBF pays quarterly β 4 times per year. Next ex-div: TBD.
How TRSBF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024β2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for TRSBF sourced from FMP /financial-growth endpoint β real data, not estimates.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores β lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the TRSBF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer β
3SBio Inc. (TRSBF) is currently trading at $2.15, 53% below its 52-week high. The current dividend yield is 1.48% based on an annual payout of $0.03 per share.
3SBio Inc. (TRSBF) is a healthcare stock currently trading at $2.15 with a dividend yield of 1.48%. The company pays an annual dividend of $0.03 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only β not financial advice.
News aggregated from public sources via Finnhub & RSS. For informational purposes only.
Real users. No sign-up required to leave a review.
βFinally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.β
βI've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly β $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.β
βReally solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.β
βAs someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.β
βThe Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.β
Reviews reflect users' personal experiences. Not financial advice.
Leave a review βIf DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
β±οΈ Takes 30 seconds Β· No signup Β· Free forever